Clinical Trial Search

Primary: Number of Participants With the Composite Endpoint of MACCE — 23; 121 Participants — p=<0.001

Primary: Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs) — 7 Participants

Primary: Average Daily Pain Score (ADPS) for DS-5565 — 4.77; 5.58; 7.08; 7.38 score on a scale

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: The Number of Subjects Experiencing AEs — 11; 14; 12 participants

Primary: Rate of Discontinuation of Index Treatment (Olodaterol/Tiotropium Bromide or Umeclidinium/Vilanterol) — 1826.00; 1647.03 Events per 1000 person-years

Primary: Feasibility of Attending the Yoga Program — 28.9 visual analogue scale, 0 to 100

Primary: Percentage of Participants With a ≥ 1-point Improvement (Decrease) on the Allergan Chin Retrusion Scale (ACSR) Score — 56.3; 27.5 percentage of participants — p=0.0019

Primary: Percentage of Hospice IDT Members Who Complete Required Education and Training — 92 percentage of participants

Primary: Specificity of ORI to Detect Drops in Oxygenation — 98.50; 96.68; 98.89; 96.95 percentage of true negative

Primary: Child Body Mass Index (BMI) — 1.6; 1.5; 1.7; 1.6 units on a scale

Primary: Number of Participants With Adverse Drug Reactions — 62; 5 Participants

Primary: Number of Participants With Evaluable fMRI Scans — 9; 9; 9; 9 participants

Primary: Radiographic Response Rate — 1; 6; 10 Participants

Primary: Percentage of Patients Who Made an Appointment for Behavioral Therapy — 37.5; 22.2 percentage of participants